ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · Real-Time Price · USD
1.570
+0.010 (0.64%)
At close: May 26, 2026, 4:00 PM EDT
1.630
+0.060 (3.82%)
After-hours: May 26, 2026, 5:21 PM EDT
ProQR Therapeutics Revenue
ProQR Therapeutics had revenue of 2.03M EUR in the quarter ending March 31, 2026, a decrease of -57.12%. This brings the company's revenue in the last twelve months to 13.64M, down -30.51% year-over-year. In the year 2025, ProQR Therapeutics had annual revenue of 16.35M, down -16.36%.
Revenue (ttm)
13.64M EUR
Revenue Growth
-30.51%
P/S Ratio
10.49
Revenue / Employee
73,092 EUR
Employees
187
Market Cap
165.42M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.35M | -3.20M | -16.36% |
| Dec 31, 2024 | 19.55M | 10.02M | 105.20% |
| Dec 31, 2023 | 9.53M | 5.17M | 118.51% |
| Dec 31, 2022 | 4.36M | 1.98M | 83.31% |
| Dec 31, 2021 | 2.38M | -7.07M | -74.84% |
| Dec 31, 2020 | 9.45M | 7.52M | 388.98% |
| Dec 31, 2019 | 1.93M | -3.83M | -66.45% |
| Dec 31, 2018 | 5.76M | 4.27M | 285.35% |
| Dec 31, 2017 | 1.50M | -333.00K | -18.22% |
| Dec 31, 2016 | 1.83M | -1.41M | -43.49% |
| Dec 31, 2015 | 3.24M | 2.92M | 933.55% |
| Dec 31, 2014 | 313.00K | 197.00K | 169.83% |
| Dec 31, 2013 | 116.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| Protalix BioTherapeutics | 76.38M |
| Spero Therapeutics | 61.19M |
| Korro Bio | 3.84M |
| Oramed Pharmaceuticals | 2.00M |
PRQR News
- 14 days ago - ProQR Announces First Quarter 2026 Operating and Financial Results - GlobeNewsWire
- 14 days ago - ProQR Therapeutics Earnings release: Q1 2026 - Filings
- 15 days ago - ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform - GlobeNewsWire
- 22 days ago - ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 - GlobeNewsWire
- 26 days ago - ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors - GlobeNewsWire
- 6 weeks ago - ProQR Therapeutics management to meet with Cantor Fitzgerald - TheFly
- 6 weeks ago - ProQR Therapeutics management to meet with Oppenheimer - TheFly
- 6 weeks ago - ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event - GlobeNewsWire